$GYRE Balance Sheet | Understand Stock

$GYRE

$6.51 +$0.44 (7.17%) Live

$GYRE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current assets:
Cash and cash equivalents
Accounts and other receivables
Short-term bank deposits
Accounts and note receivables, net
Short-term investment
Notes receivable
Accounts receivables, net
Other receivables from GNI
Prepaid insurance
Prepaid and other current assets
Prepaid assets
Receivable from GCBP
Other current assets
Inventories, net
Prepaid assets and other current assets
Total current assets

Long-term investments
Property and equipment, net
Long-term receivable from GCBP
Intangible assets, net
Right-of-use assets
Land use rights, net
Long-term prepayments
Deferred tax assets
Long-term certificates of deposit
Other assets, noncurrent
Total assets
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
Accrued compensation
Other accrued liabilities
Dividends payable
Contract liabilities
Deferred revenue
Due to related parties
CVR excess closing cash payable
Accrued expenses and other current liabilities
Income tax payable
Operating lease liabilities, current
CVR derivative liability
Total current liabilities

Operating lease liabilities, noncurrent
Deferred government grants
CVR derivative liability, noncurrent
Warrant liability, noncurrent
Other noncurrent liabilities
Total liabilities
Temporary Equity, Carrying Amount
Series B Preferred Stock (as Converted)
Redeemable Convertible Preferred Stock
Redeemable Preferred Stock
Convertible Preferred Stock

Stockholders' equity:
Convertible preferred stock, $0.001 par value, 123,418 shares authorized; 12,340 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value, 400,000,000 shares authorized; 106,033,763 shares and 91,314,007 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Statutory reserve
Accumulated deficit
Accumulated other comprehensive income (loss)
Total Gyre stockholders' equity
Noncontrolling interest
Total equity
Total liabilities, Series B preferred stock, redeemable convertible preferred stock, and stockholders' equity

Comments